From: The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
 | OM3CA (Epanova) [17] | OM3EE (Lovaza) [14] | IPE (Vascepa) [16] | ||||
---|---|---|---|---|---|---|---|
Parameter | Placebo (olive oil) (n = 100) | OM3CA 2 g/day (n = 100) | OM3CA 4 g/day (n = 99) | Placebo (corn oil) (n = 42) | OM3EE 4 g/day (n = 42) | Placebo (mineral oil) (n = 75) | IPE 4 g/day (n = 76) |
TG | Â | Â | Â | Â | Â | Â | Â |
 Median BL, mg/dL | 682 | 717 | 655 | 788 | 816 | 703 | 680 |
 Median percentage change from BL, % | −10 | −25 | −31 | 7 | −45 | 10 | −27 |
 Difference‡ | – | −16** | −21*** | – | −52 | – | −33*** |
Non-HDL-C | Â | Â | Â | Â | Â | Â | Â |
 Median BL, mg/dL | 215 | 205 | 225 | 292 | 271 | 229 | 225 |
 Median percentage change from BL, % | −1 | −8 | −8 | −4 | −14 | 8 | −8 |
 Difference‡ | – | −7* | −10** | – | −10 | – | −18 |
HDL-C | Â | Â | Â | Â | Â | Â | Â |
 Median BL, mg/dL | 29 | 27 | 29 | 24 | 22 | 27 | 27 |
 Median percentage change form BL, % | 2 | 7 | 5 | 0 | 9 | 0 | −4 |
 Difference‡ | – | 5†| 4†| – | 9 | – | −4 |
Total cholesterol | Â | Â | Â | Â | Â | Â | Â |
 Median BL, mg/dL | 246 | 241 | 254 | 314 | 296 | 256 | 254 |
 Median percentage change from BL, % | 0 | −6 | −6 | −2 | −10 | 8 | −7 |
 Difference‡ | – | −6 | −9 | – | −8 | – | −16 |
VLDL-C | Â | Â | Â | Â | Â | Â | Â |
 Median BL, mg/dL | 125 | 123 | 126 | 175 | 175 | 124 | 123 |
 Median percentage change from BL, % | −11 | −25 | −35 | −1 | −42 | 14 | −20 |
 Difference‡ | – | −14 | −21 | – | −41 | – | −29* |
LDL-C | Â | Â | Â | Â | Â | Â | Â |
 Median BL, mg/dL | 78 | 77 | 90 | 108 | 89 | 86 | 91 |
 Median percentage change from BL, % | 10 | 21 | 26 | −5 | 45 | −3 | −5 |
 Difference‡ | – | 13 | 15 | – | 49 | – | −2 |
ApoB | Â | Â | Â | Â | Â | Â | Â |
 Median BL, mg/dL | 110 | 114 | 118 | ND | ND | 118 | 121 |
 Median percentage change from BL, % | 2 | 6 | 6 | ND | ND | 4 | −4 |
 Difference‡ | – | 3 | 2 | – | ND | – | −9* |